![1.jpg 1.jpg](/SupplyImg/2023-12-05/6383739141589606936830408.jpg)
TL1A产品信息
英文名称:Tumor necrosis factor superfamily member 15
中文名称:肿瘤坏死因子超家族成员15
靶点别称:TL1A, VEGI, TNFSF15
物种:人/鼠/食蟹猴/兔等
属性:重组蛋白/细胞株
标记:Biotin-labeled / Unconjugated
表达区间及表达系统(Source)
Human TL1A, His Tag (TLA-H5243) is expressed from human 293 cells (HEK293). It contains AA Leu 72- Leu 251 (Accession # O95150-1 ).
Predicted N-terminus: His
蛋白结构(Molecular Characterization)
![2.jpg 2.jpg](/SupplyImg/2023-12-05/6383739147701956535411751.jpg)
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 22.4 kDa. The protein migrates as 26 kDa and 28-30 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
内毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
纯度(Purity)
>90% as determined by SDS-PAGE.
制剂(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
1. -20°C to -70°C for 12 months in lyophilized state;
2. -70°C for 3 months under sterile conditions after reconstitution.
![3.jpg 3.jpg](/SupplyImg/2023-12-05/6383739148838021513753112.jpg)
背景(Background)
TNF样细胞因子1A(TL1A)及其受体、死亡受体3(DR3)和诱饵受体3(DcR3)分别是TNF和TNF受体蛋白超家族的成员。APC衍生的TL1A与淋巴细胞DR3的结合为活化的淋巴细胞提供了共刺激信号。DR3信号不仅影响效应淋巴细胞的增殖活性和细胞因子的产生,还严重影响调节性T细胞的发育和抑制功能。然而,DcR3限制了TL1A/DR3复合物的功能:减弱T细胞活化并下调促炎细胞因子的分泌。与DR3和DcR3一起,TL1A构成了一个细胞因子系统,积极干扰免疫反应的调节。
TL1A用户真实评价
![4.jpg 4.jpg](/SupplyImg/2023-12-05/6383739149809177068688455.jpg)
关键字: TL1A;TL1A蛋白;TL1A重组蛋白;TNFSF15;TNFSF15蛋白;
百普赛斯集团ACROBiosystems Group(股票代码:301080)是成立于2010年的跨国生物科技公司,是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球,横跨亚洲、北美洲、欧洲,在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家,与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。